The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what The FDA didn't bring peptides back. It opened a formal docket. And that distinction matters. This is not a blanket approval. Not a wellness free for all. Not one announcement that changes everything overnight. Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy